Bio-Pharma Logistics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Bio-Pharma Logistics Market Trends and Insights

Surge in High-Value Biologicals & Specialty Pharma Elevating Cold-Chain Demand

Cold-chain failures cost the sector USD 35 billion annually, underscoring the financial imperative for resilient temperature management. Logistics providers deploy AI-driven predictive analytics to foresee excursion risks, while security upgrades counter rising counterfeit threats. Frontier Scientific Solutions invested USD 1.5 billion in Foreign Trade Zone infrastructure around Wilmington and Shannon airports to cut transit times and safeguard high-value biologics ^{[1]Frontier Scientific Solutions, “FTZ Investments Enhance Biologics Cold-Chain Corridor,” biopharminternational.com}.

Advanced Therapies Growth (mRNA, Cell & Gene) Necessitating Ultra-Low-Temperature Logistics

mRNA and viral-vector products require storage as low as −150 °C. Cryoport and SK Pharmteco launched an integrated platform spanning manufacturing and distribution tailored to such therapies^{[2]Cryoport Systems, “Cryoport and SK pharmteco Announce Integrated Advanced-Therapies Supply-Chain Platform,” cryoport.com}. Research into thermostable lipids that preserve mRNA at standard refrigeration may ease dependence on deep-freeze networks, yet current pipelines still rely heavily on cryogenic infrastructure. DHL’s acquisition of CRYOPDP, handling more than 600,000 ultra-cold consignments annually, illustrates consolidation around specialized capacity.

Globalization & Decentralization of Clinical Trials Accelerating Direct-to-Patient Shipments

Decentralized trials lift recruitment and retention, but shift logistics from depot-to-site to home delivery. Sponsors now demand flexible, demand-led inventory models plus tele-health coordination. FedEx expanded Life Science Centers across Asia and rolled out sensor-based tracking to manage residential temperature control ^{[3]FedEx Expands Life Science Centres Across Asia with Sensor-Based Tracking,” BioSpectrum Asia, biospectrumasia.com}.

Stringent Worldwide GDP/GxP Compliance Mandating Outsourcing to Certified 3PLs

The EMA’s 2025 return to strict GDP certification and India’s revised Schedule M enforce global best practices, prompting drug makers to outsource to networks like Kuehne+Nagel’s 270 GxP-certified sites. In the United States, the Drug Supply Chain Security Act’s serialization regime further elevates compliance complexity.

Capacity Constraints in Temperature-Controlled Airfreight & LN₂/Dry-Ice Supply Driving Cost Volatility

Dry-ice shortages during the COVID-19 vaccine rollout revealed a fragile supply base. Air separation units wrestle with high energy prices, while airfreight belly-hold capacity competes with e-commerce. Vienna Airport’s Pharma Handling Center doubled cold-chain space, yet forward bookings still exceed slot availability, causing rate spikes and forcing mode shifts.

Divergent Global Regulatory & Customs Requirements Causing Delays and Excursion Risk

Only 14% of U.S. dispensers were DSCSA-ready before the FDA’s enforcement grace period, and error rates of 30% in EPCIS data risk shipment quarantines. China’s Anti-Espionage Law has delayed Western inspections, while the EU Medical Device Regulation backlog slows combination-product clearances, collectively prolonging border dwell times and heightening excursion risk.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Service: Value-Added Services Outpace Traditional Transportation

Transportation accounted for 70.12% of bio pharma logistics market revenue in 2025, anchored by road networks for last-mile and air corridors for time-critical biologics. Nonetheless, value-added services are forecast to grow 10.77% annually to 2031 as clients demand labeling, kitting, and qualified-person release alongside core transport. Providers leverage AI in warehouses to anticipate capacity peaks and prevent temperature deviations. Catalent’s FastChain platform illustrates the shift toward demand-led fulfilment, pairing real-time inventory with regional depots. The bio pharma logistics market size for value-added services is projected to widen steadily, reflecting regulatory complexity and patient-centric packaging needs. Transportation will retain scale but face pricing pressure as supply tightens in temperature-controlled trucking and airfreight.

Within transport, road logistics remains dominant for sub-zero deliveries across continental networks, while air plays a critical role in ultra-cold gene-therapy consignments despite ongoing capacity constraints. Sea freight gains modest share as sustainability targets drive modal shifts for stable biologics. Warehousing growth tracks with clients’ off-site storage preferences, particularly in Europe where new GMP-compliant cold rooms unlock cross-border distribution.

By Temperature Range: Cold Chain Dominance Amid Ultra-Cold Growth

Cold chain services captured 68.40% of the bio pharma logistics market in 2025 and will expand fastest at 10.49% CAGR. Refrigerated (2-8 °C) lanes underpin vaccines and insulin flows, yet ultra-cold (−20 °C to −150 °C) emerges as the star sub-segment for mRNA and cell & gene therapies. The bio pharma logistics market size tied to ultra-cold shipments is forecast to nearly double by 2031. Providers invest in vacuum-insulated panels, phase-change materials, and nitrogen-based dry shippers with IoT beacons for live temperature feeds.

Ambient (15-25 °C) networks continue to serve traditional oral solids but grow slower as formularies tilt toward biologics. Frozen (0 °C to −20 °C) remains niche for specific APIs and long-term stockpiles. Sustainability imperatives accelerate a pivot to reusable shippers and electrified reefers, creating hybrid models pairing green power with dense thermal mass. Blockchain pilots track chain-of-custody events to assure compliance.

By Product Type: Cell & Gene Therapies Lead Innovation-Driven Growth

Vaccines and immunotherapies led 2025 revenue with a 36.74% share, buoyed by ongoing public-health programs. Yet, cell & gene therapies headline growth at 13.05% CAGR through 2031, pushing demand for bespoke, monitored containers. Cold-chain qualified packaging for viral vectors incorporates vibration-damping and slow-release dry ice. The bio-pharma logistics market share for vaccines will moderate as prophylactic programs stabilize, while APIs and bulk biologics maintain steady volume into large-scale plants.

Advanced analytical testing, such as ion-pair reversed-phase chromatography for mRNA impurity profiling, lengthens pre-release lead times, making secure interim storage vital. Finished-dose biologics benefit from efficiencies in fill-finish plants but still depend on end-to-end cold visibility.

By End-User: CROs and CMOs Drive Outsourcing Acceleration

Bio-pharma manufacturers held 58.10% revenue share in 2025; however, CROs/CMOs grow fastest at 12.02% CAGR as firms outsource complexity. That shift multiplies shipment lanes because each CMO services multiple sponsors. Hospitals and trial sites require direct-to-patient options and flexible resupply. The bio pharma logistics market size allocated to CRO/CMO workstreams will therefore rise disproportionately, attracting specialist carriers with clinical-trial licensure and remote-visit expertise.

Manufacturers still command bulk volume, leveraging long-term contracts with integrators to secure capacity. Specialty pharmacies and emerging direct-therapist delivery models form a diversifying tail, each demanding granular tracking for chain-of-identity.

Geography Analysis

North America retained 41.20% share of the bio pharma logistics market in 2025 on the back of entrenched pharmaceutical manufacturing, dense GDP-certified networks, and the early adoption of IoT-enabled monitoring. Major capex programs, such as UPS’s USD 1.6 billion acquisition of Andlauer Healthcare Group, deepen regional infrastructure and reinforce standards leadership.

Asia-Pacific is projected to grow at 11.06% CAGR and will account for the majority of the incremental market value through 2031. Chinese innovators are relocating vector production to Singapore and Thailand to diversify risk, while India expands injectables output under revised GMP rules. Singapore’s new multi-tenant pharma hub embodies the region’s push for high-grade cold storage and cross-border rapid clearance. As a result, the bio-pharma logistics market size related to intra-Asia trade lanes is set to accelerate.

Europe remains a powerhouse, leveraging tight regulatory compliance and extensive road-rail cold corridors. DHL’s 30,000 m² climate-neutral expansion near Frankfurt supports sub-zero warehousing down to −70 °C, reinforcing the continent’s capability to manage cell & gene therapy pipelines. Ongoing consolidation raises service quality, though capacity constraints persist at key cargo gateways like Schiphol and Brussels.

South America and the Middle East & Africa exhibit emerging opportunity profiles. Government vaccine campaigns and growing chronic-disease treatment uptake catalyze the need for certified cold rooms and road-to-air interfaces. However, patchy power grids and limited GDP oversight pose service-quality challenges, slowing the pace of infrastructure upgrades.

Regulatory Landscape

Bio-pharma logistics operations are managed under GDP and broader GxP requirements covering how medicinal products are stored, handled, transported, and documented across multi-party networks. In the EU, GDP guidance for medicinal products (2013/C 343/01) and for active substances (2015/C 95/01), implemented through EudraLex Volume 4 and enforced by national competent authorities, tightens the bar for audit-ready temperature control, supplier qualification, and lane validation. This aligns with the report context that the EMA ended blanket GDP certificate extensions in 2025, which increases reliance on certified third-party logistics partners.

Global alignment is reinforced by WHO Good Distribution Practices (TRS 957 Annex 5 and TRS 1025 Annex 7), which are used as reference frameworks in markets building or updating GDP systems. For veterinary supply chains, Commission Implementing Regulations (EU) 2025/2091 and (EU) 2025/2154 entered into full application on 16 July 2026, adding another compliance layer for operators serving multi-species portfolios and shared infrastructures. Regulators and auditors have also broadened attention to last-mile and direct-to-patient/direct-to-hospital models, raising expectations around courier qualification, temperature mapping, and data integrity in distributed delivery networks.

Value Chain Analysis

The value chain starts with biopharma manufacturers, CROs/CMOs, and clinical-trial sponsors that set product stability profiles and release needs, including labeling, kitting, and qualified-person release. They then select compliant packaging (passive PCM shippers, dry-ice solutions, or cryogenic shippers for ultra-cold lanes) and monitoring devices. Upstream suppliers include packaging and sensor/IoT module providers, dry-ice and liquid-nitrogen supply partners, and validation service firms that qualify pack-outs, routes, and handling SOPs. This work is followed by freight forwarders, airlines, ground handlers, and integrators running GDP-aligned control towers, then multi-temperature warehousing and distribution nodes placed near airports, seaports, and dense patient populations.

Execution depends on certified infrastructure and standardization across handoffs, with IATA CEIV Pharma often used as a procurement anchor for auditing airlines, handlers, and forwarders against GDP alongside IATA temperature-control practices. The chain is increasingly organized around regional, automated, multi-temperature campuses to reduce transfer time and excursion risk. This is illustrated by DHL Supply Chain taking over management of Sanofi's vaccine distribution center in Val-de-Reuil, France (February 2026) and McKesson selecting Moore, Oklahoma for a 330,000-square-foot highly automated regional pharmaceutical distribution facility with expanded cold-chain capacity and full standby power (June 2026). Cross-docking at air gateways and compliant last-mile partners remain common bottlenecks, especially for time-critical biologics and decentralized clinical-trial shipments, where multiple small consignments increase scan, data, and temperature-control requirements.

Market Opportunities and Future Outlook

One opportunity is expanding and upgrading multi-temperature storage and transfer infrastructure at major pharma nodes, particularly for biologics, vaccines, and advanced therapies where tighter control is needed at handoff points. Capacity additions in 2026 point to active whitespace filling, including Movianto expanding its Aalst, Belgium site to increase temperature-controlled pallet storage and Langham Logistics opening a large cold-chain facility in Plainfield, Indiana, with significant 2-8 C capacity. These investments support shippers that want to reduce dwell times and excursion risk, while managing higher SKU complexity and smaller shipment sizes tied to specialty medicines and clinical-trial distribution.

Another opportunity is integrated, data-driven cold-chain execution that ties together packaging, monitoring, and orchestration across modes and partners. UPS announced a USD 48 million investment in 27 temperature-controlled cross-dock facilities across the Americas, Europe, and Asia (June 2026), and DHL expanded an airfreight cold-chain network with a dedicated Brussels-Cincinnati Boeing 777 freighter lane (February 2026), reflecting continued build-out of time-critical lanes for high-value products. Services that operationalize compliance also support growth in value-added offerings, including labeling, kitting, and qualified-person release, alongside control-tower models. This demand is reinforced as direct-to-patient and decentralized trial logistics increase the number of touchpoints requiring auditable temperature and chain-of-custody data.